Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives

Epigenetics

Volumn 11, Issue 12, 2016, Pages 858-870

  Schiffmann, Insa ^a,b   Greve, Gabriele ^a,c   Jung, Manfred ^c,d   Lübbert, Michael ^a,b,d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chromatin; DNA methylation; DNMT; epigenetics; histone modifications; LSD1; lung cancer; NSCLC

Indexed keywords

ABEXINOSTAT; APICIDIN; AZACITIDINE; BELINOSTAT; DACINOSTAT; DECITABINE; DEOXYCYTIDINE; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; GIVINOSTAT; GUADECITABINE; HYDRALAZINE; MG 98; N PHTHALOYLTRYPTOPHAN; OXAMFLATIN; PANOBINOSTAT; PRACINOSTAT; PROCAINAMIDE; QUISINOSTAT; RESMINOSTAT; RICOLINOSTAT; SGI 1027; SINEFUNGIN; TIOGUANINE; TRAPOXIN A; TRAPOXIN B; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; ZEBULARINE; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR;

BIOLOGICAL ACTIVITY; DNA METHYLATION ASSAY; EPIGENETICS; EVOLUTION; HISTONE METHYLATION; HUMAN; IMMUNOPATHOLOGY; NEOPLASM; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; DNA METHYLATION; GENETIC EPIGENESIS; GENETICS; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DNA METHYLATION; DNA MODIFICATION METHYLASES; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOTHERAPY;

EID: 85008262924     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.1080/15592294.2016.1237345     Document Type: Review

References (106)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
2. Miller CP, Singh MM, Rivera-Del Valle N, Manton CA, Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol 2011; 2011:514261; PMID:21765634; http://dx.doi.org/10.1155/2011/514261.
3. Baylin SB, Jones PA. The next 10 years — Timeline:A decade of exploring the cancer epigenome — biological and translational implications. Nat Rev Cancer 2011; 11:726-34; http://dx.doi.org/10.1038/nrc3130.
4. Kouzarides T. Chromatin Modifications and Their Function. Cell 2007; 128:693-705; PMID:17320507; http://dx.doi.org/10.1016/j.cell.2007.02.005
5. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res 2011; 21:381-95; PMID:21321607; http://dx.doi.org/10.1038/cr.2011.22
6. Herman JG, Baylin SB. Gene Silencing in Cancer in Association with Promoter Hypermethylation. N Engl J Med 2003; 349:2042-54; PMID:14627790; http://dx.doi.org/10.1056/NEJMra023075
7. Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W, et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 2015; 527:1-16; http://dx.doi.org/10.1038/527S1a
8. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5:769-84; PMID:16955068; http://dx.doi.org/10.1038/nrd2133
9. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma:pivotal study update demonstrates durable responses. J Hematol Oncol 2014; 7:11; PMID:24456586; http://dx.doi.org/10.1186/1756-8722-7-11
10. Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 2015; 26:1766-71; http://dx.doi.org/10.1093/annonc/mdv237.
11. Campbell P, Thomas CM. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma. J Oncol Pharm Pr 2016; http://dx.doi.org/10.1177/1078155216634178.
12. Mu S, Tajima T, Corrado C, Suzuki K, Hino M, Kuroda Y, Shibayama H, Lin R, Waldron E, Binlich F. Panobinostat PK/PD in combination with bortezomib and dexamethasone in patients withrelapsed and relapsed/ refractory multiple myeloma (RRMM). Clin Pharmacol Ther 2015; 97:S49; http://dx.doi.org/10.1007/s00228-015-1967-z
13. Hoffmann I, Roatsch M, Schmitt ML, Carlino L, Pippel M, Sippl W, Jung M. The role of histone demethylases in cancer therapy. Mol Oncol 2012; 6:683-703; PMID:22902149; http://dx.doi.org/10.1016/j.molonc.2012.07.004
14. Morera L, Lübbert M, Jung M. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy. Clin Epigenet 2016
15. Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X, Song Y. Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One 2012; 7:e35065; PMID:22493729; http://dx.doi.org/10.1371/journal.pone.0035065
16. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012; 21:473-87; PMID:22464800; http://dx.doi.org/10.1016/j.ccr.2012.03.014
17. Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med 2012; 18:605-11; PMID:22406747; http://dx.doi.org/10.1038/nm.2661
18. Mould DP, McGonagle AE, Wiseman DH, Williams EL, Jordan AM. Reversible Inhibitors of LSD1 as Therapeutic Agents in Acute Myeloid Leukemia:Clinical Significance and Progress to Date. Med Res Rev 2014; 35:586-618; http://dx.doi.org/10.1002/med.21334.
19. Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 2012; 29:997-1003; http://dx.doi.org/10.1016/j.lungcan.2012.08.003
20. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223-32; PMID:19230772; http://dx.doi.org/10.1016/S1470-2045(09)70003-8
21. Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015; 126:291-300; PMID:25987659; http://dx.doi.org/10.1182/blood-2015-01-621664
22. Kantarjian H, Issa J-PJ, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer [Internet] 2006; 106:1794-803; PMID:16532500; http://dx.doi.org/10.1002/cncr.21792
23. Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, et al. Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy:Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS. J Clin Oncol 2011; 29:1987-96; PMID:21483003; http://dx.doi.org/10.1200/JCO.2010.30.9245
24. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010; 107:7473-8; PMID:20368434; http://dx.doi.org/10.1073/pnas.1002650107
25. Cruijsen M, Lübbert M, Wijermans P, Huls G. Clinical Results of Hypomethylating Agents in AML Treatment. J Clin Med 2014; 4:1-17; PMID:26237015; http://dx.doi.org/10.3390/jcm4010001
26. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, et al. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol [Internet] 2012; 30:1-10; http://dx.doi.org/10.1200/JCO.2011.38.9429.
27. San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Günther A, Nakorn TN, Siritanaratkul N, et al. Panobinostat plus bortezomib and dexamethasone vs. placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma:a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol 2014; 15:1195-206; PMID:25242045; http://dx.doi.org/10.1016/S1470-2045(14)70440-1
28. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995; 1:686-92; PMID:7585152; http://dx.doi.org/10.1038/nm0795-686
29. Gomes A, Reis-Silva M, Alarcão A, Couceiro P, Sousa V, Carvalho L. Promoter hypermethylation of DNA repair genes MLH1 and MSH2 in adenocarcinomas and squamous cell carcinomas of the lung. Rev Port Pneumol 2014; 20:20-30; PMID:24360395; http://dx.doi.org/10.1016/j.rppneu.2013.07.003
30. Grote HJ, Schmiemann V, Kiel S, Böcking A, Kappes R, Gabbert HE, Sarbia M. Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer. Int J Cancer 2004; 110:751-5; PMID:15146565; http://dx.doi.org/10.1002/ijc.20196
31. Virmani AK, Rathi A, Zöchbauer-Müller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, et al. Promoter methylation and silencing of the retinoic acid receptor-β gene in lung carcinomas. J Natl Cancer Inst 2000; 92:1303-7; PMID:10944551; http://dx.doi.org/10.1093/jnci/92.16.1303
32. Do H, Wong NC, Murone C, John T, Solomon B, Mitchell PL, Dobrovic A. A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. Sci Rep 2014; 4:4186; PMID:24569633; http://dx.doi.org/10.1038/srep04186
33. Belinsky SA. Unmasking the Lung Cancer Epigenome. Annu Rev Physiol 2015; 77:453-74; PMID:25668024; http://dx.doi.org/10.1146/annurev-physiol-021014-072018
34. Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Mitsui M, Motoyama S, Ogawa J. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2011; 74:300-4; PMID:21466904; http://dx.doi.org/10.1016/j.lungcan.2011.02.019
35. Song JS, Kim YS, Kim DK, Park S, Il Jang SJ. Global histone modification pattern associated with recurrence and disease-free survival in non-small cell lung cancer patients. Pathol Int 2012; 62:182-90; PMID:22360506; http://dx.doi.org/10.1111/j.1440-1827.2011.02776.x
36. Barlési F, Giaccone G, Gallegos-Ruiz MI, Loundou A, Span SW, Lefesvre P, Kruyt FA, Rodriguez JA. Global histone modifications predict prognosis of resected non-small-cell lung cancer. J Clin Oncol 2007; 25:4358-64; http://dx.doi.org/10.1200/JCO.2007.11.2599
37. Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, et al. A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol 2013; 31:4140-7; PMID:24081945; http://dx.doi.org/10.1200/JCO.2012.48.5516
38. Momparler RL. Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2′-deoxycytidine). Front Oncol 2013; 3:188; PMID:23908969; http://dx.doi.org/10.3389/fonc.2013.00188
39. Gridelli C, Rossi A, Maione P. The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol 2008; 68:29-36; PMID:18424067; http://dx.doi.org/10.1016/j.critrevonc.2008.03.002
40. Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells. Lung Cancer 2012; 78:138-43; PMID:22925699; http://dx.doi.org/10.1016/j.lungcan.2012.08.003
41. Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, Schoeffski P. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 2008; 26:483-8; PMID:18425418; http://dx.doi.org/10.1007/s10637-008-9131-6
42. Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011; 1:598-607; PMID:22586682; http://dx.doi.org/10.1158/2159-8290.CD-11-0214
43. Yoo CB, Jones PA. Epigenetic therapy of cancer:past, present and future. Nat Rev Drug Discov 2006; 5:37-50; PMID:16485345; http://dx.doi.org/10.1038/nrd1930
44. Tang J, Salama R, Gadgeel SM, Sarkar FH, Ahmad A. Erlotinib resistance in lung cancer:current progress and future perspectives. Front Pharmacol 2013; 4:15; PMID:23407898; http://dx.doi.org/10.3389/fphar.2013.00015
45. Füller M, Klein M, Schmidt E, Rohde C, Göllner S, Schulze I, Qianli J, Berdel W, Edemir B, Müller-Tidow C, et al. 5-Azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation. Int J Oncol 2014; 46:1192-204; PMID:25501798; http://dx.doi.org/10.3892/ijo.2014.2792.
46. Li XY, Wu JZ, Cao HX, Ma R, Wu JQ, Zhong YJ, Feng JF. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells. Oncol Rep 2013; 29:1975-82; PMID:23440266; http://dx.doi.org/10.3892/or.2013.2298.
47. Kim HJ, Kim JH, Chie EK, Park DY, Kim IA, Kim IH. DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity. Radiat Oncol 2012; 7:39; PMID:22429326; http://dx.doi.org/10.1186/1748-717X-7-39
48. Zuco V, de Cesare M, Cincinelli R, Nannei R, Pisano C, Zaffaroni N, Zunino F. Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo. PLoS One 2011; 6:1-12; http://dx.doi.org/10.1371/journal.pone.0029085
49. Zhang Q, Jiang S, Zhang S, Ma X. Histone Deacetylase Inhibitor Trichostatin A Enhances Anti- tumor Effects of Docetaxel or Erlotinib in A549 Cell Line. 2012; 13:3471-6; PMID:22994780; http://dx.doi.org/10.7314/APJCP.2012.13.7.3471.
50. Del Bufalo D, Desideri M, De Luca T, Di Martile M, Gabellini C, Monica V, Busso S, Eramo A, De Maria R, Milella M, et al. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. Mol Cancer 2014; 13:230; http://dx.doi.org/10.1186/1476-4598-13-230.
51. Frenkel EP. Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC). Cell Lines 2009; 4:161-6; http://dx.doi.org/10.1097/JTO.0b013e318194fae7.
52. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006; 66:944-50; PMID:16424029; http://dx.doi.org/10.1158/0008-5472.CAN-05-1988
53. Greve G, Schiffmann I, Pfeifer D, Pantic M, Schüler J, Lübbert M. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells. BMC Cancer. 2015;15(1):947; http://dx.doi.org/10.1186/s12885-015-1967-5.
54. Greve G, Schiffmann I, Lübbert M. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid. J Cancer Res Clin Oncol 2015; 141:2171-80; PMID:26008188; http://dx.doi.org/10.1007/s00432-015-1987-1.
55. Han S, Fukazawa T, Yamatsuji T, Matsuoka J, Miyachi H, Maeda Y, Durbin M, Naomoto Y. Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors:SL142 or SL325 and retinoic acids. PLoS One 2010; 5:e13834; PMID:21079797; http://dx.doi.org/10.1371/journal.pone.0013834
56. Gavrilov V, Lavrenkov K, Ariad S. Sodium Valproate, a Histone Deacetylase Inhibitor, Enhances the Efficacy of Vinorelbine-Cisplatin- based Chemoradiation in Non-small Cell Lung Cancer Cells. Anticancer Res 2014; 34:6572
57. Zhang F, Zhang T, Teng ZH, Zhang R, Wang JB, Mei QB. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol Ther 2009; 8:823-31; PMID:19270532; http://dx.doi.org/10.4161/cbt.8.9.8143
58. Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, Zhang H, Marquez VE, Hammerman PS, Wong KK, et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 2015; 520:239-42; PMID:25629630; http://dx.doi.org/10.1038/nature14122
59. Vasilatos SN, Katz TA, Oesterreich S, Wan Y, Davidson NE, Huang Y. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis 2013; 34:1196-207; PMID:23354309; http://dx.doi.org/10.1093/carcin/bgt033
60. Kondo Y. Epigenetic cross-talk between DNA methylation and histone modifications in human cancers. Yonsei Med J 2009; 50:455-63; PMID:19718392; http://dx.doi.org/10.3349/ymj.2009.50.4.455
61. Guillemette B, Drogaris P, Lin HH, Armstrong H, Hiragami-Hamada K, Imhof A, Bonneil E, Thibault P, Verreault A, Festenstein RJ. H3 lysine 4 is acetylated at active gene promoters and is regulated by H3 lysine 4 methylation. PLoS Genet 2011; 7:e1001354; http://dx.doi.org/10.1371/journal.pgen.1001354.
62. Takashina T, Kinoshita I, Kikuchi J, Shimizu Y, Konishi JS, Oizumi S, Nishimura M, Akita HD. Abstract 5162:Effects of combined epigenetic therapy with histone methyltransferase EZH2 inhibitor 3-deazaneplanocin and histone deacetylase inhibitor SAHA on non-small cell lung cancer cells. Cancer Res 2014; 74:5162-2; http://dx.doi.org/10.1158/1538-7445.AM2014-5162
63. Belinsky SA, Grimes MJ, Picchi MA, Mitchell HD, Stidley CA, Tesfaigzi Y, Channell MM, Liu Y, Casero RA, Baylin SB, et al. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 2011; 71:454-62; PMID:21224363; http://dx.doi.org/10.1158/0008-5472.CAN-10-3184
64. Vendetti FP, Topper M, Huang P, Dobromilskaya I, Easwaran H, Wrangle J, Baylin SB, Poirier JT, Rudin CM. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget 2015; 6:56-70; PMID:25474141; http://dx.doi.org/10.18632/oncotarget.2695.
65. Momparler RL. Pilot phase I-II study on 5-aza-2′deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anti-Cander Drugs 1997; 53:358-68; PMID:9074840; http://dx.doi.org/10.1097/00001813-199704000-00008
66. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006; 12:5777-85; PMID:17020984; http://dx.doi.org/10.1158/1078-0432.CCR-06-0669
67. Traynor AM, Dubey S, Eickhoff JC, Kolesar JM, Schell K, Huie MS, Groteluschen DL, Marcotte SM, Hallahan CM, Weeks HR, et al. Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer:a Wisconsin Oncology Network phase II study. J Thorac Oncol 2009; 4:522-6; PMID:19347984; http://dx.doi.org/10.1097/JTO.0b013e3181952478
68. Otterson GA, Hodgson L, Pang H, Vokes EE. Phase II study of the HDAC inhibitor romidepsin in relapsed small cell lung cancer. Changes 2012; 29:997-1003; http://dx.doi.org/10.1016/j.biotechadv.2011.08.021.
69. Bauman J, Verschraegen C, Belinsky S, Muller C, Rutledge T, Fekrazad M, Ravindranathan M, Lee SJ, Jones D. A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. Cancer Chemother Pharmacol 2012; 69:547-54; PMID:21901396; http://dx.doi.org/10.1007/s00280-011-1729-2
70. Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, Muse I, DiLeone L, Mans DR. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 2000; 18:83-91; PMID:10830142; http://dx.doi.org/10.1023/A:1006388031954
71. Jones DR, Moskaluk CA, Gillenwater HH, Petroni R, Burks SG, Philips J, Rehm PK, Kozower BD, Bao Y. Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non-small Cell Lung Cancer. J Thorac Oncol 2012; 7:1683-90; http://dx.doi.org/10.1097/JTO.0b013e318267928d.
72. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase i study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs 2013; 31:115-25; PMID:22415798; http://dx.doi.org/10.1007/s10637-012-9812-z
73. Gray J, Haura EB, Chiappori A, Tanvetyanon T, Williams CC, Pinder-Schenk M, Kish JA, Kreahling JM, Lush RM, Neuger AM, et al. A phase I, pharmacokinetic and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors. Clin Cancer Res [Internet] 2014 [cited 2014 Feb 5]; 20:1644-55; http://dx.doi.org/10.1158/1078-0432.CCR-13-2235.
74. Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, Moran T, Rolfo C, Pallarès MC, Insa A, et al. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer 2014; 84:161-7; PMID:24636848; http://dx.doi.org/10.1016/j.lungcan.2014.02.011
75. Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA, Hirsch FR. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012; 30:2248-55; PMID:22508830; http://dx.doi.org/10.1200/JCO.2011.38.9411
76. Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:56-62; PMID:19933908; http://dx.doi.org/10.1200/JCO.2009.24.9094
77. Chu BF, Karpenko MJ, Liu Z, Aimiuwu J, Villalona-Calero MA, Chan KK, Grever MR, Otterson GA. Phase i study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother Pharmacol 2013; 71:115-21; PMID:23053268; http://dx.doi.org/10.1007/s00280-012-1986-8
78. http://clinicaltrials.gov/show/NCT01628471
79. http://clinicaltrials.gov/show/NCT00978250
80. http://clinicaltrials.gov/show/NCT00423449
81. https://clinicaltrials.gov/ct2/show/record/NCT00473889
82. http://clinicaltrials.gov/show/NCT01090830
83. http://clinicaltrials.gov/show/NCT01188707
84. https://clinicaltrials.gov/ct2/show/record/NCT01935947
85. http://clinicaltrials.gov/show/NCT00387465
86. Mohammad HP, Smitheman KN, Kamat CD, Soong D, Federowicz KE, Van Aller GS, Schneck JL, Carson JD, Liu Y, Butticello M, et al. A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell 2015; 28:57-69; PMID:26175415; http://dx.doi.org/10.1016/j.ccell.2015.06.002
87. https://clinicaltrials.gov/ct2/show/NCT02034123?term#61501;GSK2879552rank1501;1
88. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, et al. Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget [Internet] 2013; 4:2067-79; PMID:24162015; http://dx.doi.org/10.18632/oncotarget.1542
89. Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med [Internet] 2012; 366:2455-65; PMID:22658128; http://dx.doi.org/10.1056/NEJMoa1200694
90. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer. N Engl J Med 2010; 362:2251-9; PMID:20525993; http://dx.doi.org/10.1056/NEJMoa0912614
91. Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell [Internet] 2015; 162:974-86. Available from:http://dx.doi.org/10.1016/j.cell.2015.07.011
92. Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, et al. DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. Cell [Internet] 2015; 162:961-73. Available from:http://dx.doi.org/10.1016/j.cell.2015.07.056
93. https://clinicaltrials.gov/ct2/show/NCT01928576
94. Brahmer J, Reckamp KL, Baas P, Crin∫ L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373:1-13; http://dx.doi.org/10.1056/NEJMoa1504627.
95. https://clinicaltrials.gov/ct2/show/NCT02546986
96. https://clinicaltrials.gov/show/NCT02437136
97. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103-7; PMID:9916800; http://dx.doi.org/10.1038/5047
98. Huang Y, Vasilatos SN, Boric L, Shaw PG, Davidson NE. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat 2012; 131:777-89; PMID:21452019; http://dx.doi.org/10.1007/s10549-011-1480-8
99. Fahy J, Jeltsch A, Arimondo PB. DNA methyltransferase inhibitors in cancer:a chemical and therapeutic patent overview and selected clinical studies. Expert Opin Ther Pat 2012; 22:1-16; PMID:22214283; http://dx.doi.org/10.1517/13543776.2012.729579
100. Ono T, Li C, Mizutani E, Terashita Y, Yamagata K, Wakayama T. Inhibition of class IIb histone deacetylase significantly improves cloning efficiency in mice. Biol Reprod [Internet] 2010; 83:929-37; http://dx.doi.org/10.1095/biolreprod.110.085282.
101. Ali A, Bluteau O, Messaoudi K, Palazzo A, Boukour S, Lordier L, Lecluse Y, Rameau P, Kraus-Berthier L, Jacquet-Bescond A, et al. Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. Cell Death Dis [Internet] 2013; 4:e738; PMID:23887629; http://dx.doi.org/10.1038/cddis.2013.260
102. Kushner BH, LaQuaglia MP, Wollner N, Meyers PA, Lindsley KL, Ghavimi F, Merchant TE, Boulad F, Cheung NK, Bonilla MA, et al. Desmoplastic small round-cell tumor:Prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol 1996; 14:1526-31; PMID:8622067; http://dx.doi.org/10.1002/pbc.
103. Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, et al. Initial Testing (Stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2010; 199:1442-8; http://dx.doi.org/10.1086/597422.
104. Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P. The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. Br J Haematol 2010; 149:518-28; PMID:20201941; http://dx.doi.org/10.1111/j.1365-2141.2010.08124.x
105. Kusaczuk M, Krętowski R, Bartoszewicz M, Cechowska-Pasko M. Phenylbutyrate - a pan-HDAC inhibitor that suppresses proliferation of glioblastoma LN-229 cell line. Tumor Biol 2016; 37:931-42; http://dx.doi.org/10.1007/s13277-015-3781-8
106. Kim DH, Shin J, Kwon HJ. Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp Mol Med [Internet] 2007; 39:47-55. PMID:17334228; http://dx.doi.org/10.1038/emm.2007.6